- Molecular NameMethohexital
- SynonymMethodrexitone; Methohexitone
- Weight262.309
- Drugbank_IDDB00474
- ACS_NO151-83-7
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)2.15
- pka8.3
- LogD (pH=7, predicted)2.11
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-3.22
- LogSw (predicted, AB/LogsW2.0)0.34
- Sw (mg/ml) (predicted, ACD/Labs)0.14
- No.of HBond Donors1
- No.of HBond Acceptors5
- No.of Rotatable Bonds5
- TPSA66.48
- StatusFDA approved
- AdministrationIntravenous, rectal
- PharmacologyA drug which is a barbiturate derivative. It is classified as short-acting, and has a rapid onset of action. It is similar in its effects to sodium thiopental, a drug with which it competed in the market for anaesthetics.
- Absorption_valueN/A
- Absorption (description)The absolute bioavailability following rectal administration of methohexital is 17%.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding73.0
- Volume of distribution (VD)1 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic
- Half life1~2 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe onset of toxicity following an overdose of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in overdose include central nervous system depression, respiratory depression, hypotension, loss of peripheral vascular resistance, and muscular hyperactivity ranging from twitching to convulsive-like movements. Other findings may include convulsions and allergic reactions. Following massive exposure to any barbiturate, pulmonary edema, circulatory collapse with loss of peripheral vascular tone, and cardiac arrest may occur.
- LD50 (rat)N/A
- LD50 (mouse)N/A